AllianceBernstein
VERV

AllianceBernstein’s Verve Therapeutics VERV Stock Holding History

AllianceBernstein’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-68,100
Closed -$765K – 3303
2025
Q2 		$765K Hold
68,100
– – ﹤0.01% 2429
2025
Q1 		$311K Sell
68,100
-5,900
-8% -$39.5K ﹤0.01% 2755
2024
Q4 		$417K Sell
74,000
-9,450
-11% -$53.3K ﹤0.01% 2718
2024
Q3 		$404K Hold
83,450
– – ﹤0.01% 2771
2024
Q2 		$407K Buy
83,450
+19,040
+30% +$120K ﹤0.01% 2776
2024
Q1 		$855K Buy
64,410
+21,910
+52% +$291K ﹤0.01% 2347
2023
Q4 		$592K Hold
42,500
– – ﹤0.01% 2527
2023
Q3 		$564K Sell
42,500
-33,170
-44% -$534K ﹤0.01% 2511
2023
Q2 		$1.42M Sell
75,670
-3,100
-4% -$51.6K ﹤0.01% 2092
2023
Q1 		$1.14M Sell
78,770
-100
-0.1% -$1.96K ﹤0.01% 2162
2022
Q4 		$1.53M Buy
78,870
+5,100
+7% +$135K ﹤0.01% 2068
2022
Q3 		$2.53M Buy
73,770
+33,570
+84% +$1.07M ﹤0.01% 1732
2022
Q2 		$614K Buy
40,200
+6,100
+18% +$94.5K ﹤0.01% 2591
2022
Q1 		$778K Buy
34,100
+20,300
+147% +$580K ﹤0.01% 2512
2021
Q4 		$509K Sell
13,800
-2,200
-14% -$92.4K ﹤0.01% 2733
2021
Q3 		$752K Buy
16,000
+9,781
+157% +$575K ﹤0.01% 2606
2021
Q2 		$375K Buy
+6,219
New +$258K ﹤0.01% 2932

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AllianceBernstein's VERV Position: Q3 2025 in Review

AllianceBernstein sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 68,100 shares — an estimated $765K sold.

AllianceBernstein first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $2.53M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • AllianceBernstein reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AllianceBernstein sold 68,100 Verve Therapeutics shares in Q3 2025, an estimated $765K.
  • AllianceBernstein first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • AllianceBernstein's Verve Therapeutics position peaked at $2.53M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on AllianceBernstein's 13F filing for Q3 2025, filed 14 Nov 2025.